Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Saketh Guntupalli

Concepts (286)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Endometrial Neoplasms
20
2024
161
4.270
 Why?
Ovarian Neoplasms
15
2024
482
3.110
 Why?
Genital Neoplasms, Female
7
2024
82
2.940
 Why?
Gynecology
8
2021
174
2.510
 Why?
Enoxaparin
4
2024
59
2.310
 Why?
Carcinoma, Endometrioid
11
2023
44
2.190
 Why?
Pyridones
4
2024
158
2.160
 Why?
Hysterectomy
11
2020
118
2.040
 Why?
Pyrazoles
4
2024
403
1.900
 Why?
Uterine Cervical Neoplasms
8
2021
230
1.790
 Why?
Fellowships and Scholarships
5
2018
279
1.790
 Why?
Obstetrics
4
2020
162
1.690
 Why?
Internship and Residency
6
2020
1058
1.480
 Why?
Venous Thromboembolism
4
2024
287
1.430
 Why?
Postoperative Complications
8
2024
2481
1.350
 Why?
Anticoagulants
4
2024
637
1.280
 Why?
Sexual Dysfunction, Physiological
2
2020
64
1.160
 Why?
Lymph Nodes
3
2017
471
1.120
 Why?
Clinical Competence
5
2020
1020
1.110
 Why?
Neoplasm Staging
18
2024
1282
0.880
 Why?
Uterine Neoplasms
3
2021
100
0.820
 Why?
Antineoplastic Combined Chemotherapy Protocols
7
2024
1560
0.770
 Why?
Female
62
2024
68829
0.740
 Why?
Middle Aged
43
2024
31177
0.730
 Why?
Treatment Adherence and Compliance
1
2021
24
0.730
 Why?
Education, Medical, Graduate
2
2016
443
0.730
 Why?
Pulmonary Embolism
1
2023
212
0.700
 Why?
Neoplasm Recurrence, Local
8
2021
957
0.690
 Why?
Carcinosarcoma
3
2017
16
0.680
 Why?
Aged
33
2024
22107
0.660
 Why?
Robotic Surgical Procedures
3
2016
113
0.650
 Why?
Intrauterine Devices
1
2019
28
0.640
 Why?
Ovariectomy
4
2015
137
0.590
 Why?
Laparotomy
2
2015
106
0.590
 Why?
Venous Thrombosis
1
2020
176
0.590
 Why?
Healthcare Disparities
3
2021
580
0.590
 Why?
Oncologists
1
2018
35
0.570
 Why?
Neoplasms
6
2024
2454
0.570
 Why?
Humans
65
2024
129847
0.560
 Why?
Quality of Health Care
2
2021
610
0.550
 Why?
Retrospective Studies
17
2024
14553
0.550
 Why?
Neoplasm Invasiveness
6
2021
484
0.540
 Why?
Sexual Dysfunctions, Psychological
1
2017
34
0.530
 Why?
Prognosis
11
2024
3773
0.520
 Why?
Attitude
1
2018
254
0.520
 Why?
Minority Groups
1
2018
250
0.510
 Why?
Aged, 80 and over
14
2023
7066
0.500
 Why?
Gynecologic Surgical Procedures
3
2024
57
0.500
 Why?
Medication Adherence
1
2020
561
0.480
 Why?
Endometrium
2
2019
56
0.470
 Why?
Radiography, Thoracic
1
2016
165
0.460
 Why?
Hemostasis, Surgical
1
2014
22
0.460
 Why?
Abdominal Abscess
1
2014
26
0.450
 Why?
Gelatin
1
2014
42
0.450
 Why?
Surgeons
1
2018
264
0.450
 Why?
Thrombin
1
2014
147
0.420
 Why?
Interpersonal Relations
1
2017
395
0.420
 Why?
WT1 Proteins
1
2013
14
0.410
 Why?
Robotics
1
2014
92
0.410
 Why?
Estrogen Receptor beta
1
2013
38
0.400
 Why?
Follow-Up Studies
9
2024
4896
0.390
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2024
90
0.390
 Why?
Adenocarcinoma
3
2021
893
0.380
 Why?
Adult
27
2024
35634
0.380
 Why?
Lymphatic Vessels
1
2011
61
0.350
 Why?
Adenocarcinoma, Clear Cell
2
2023
13
0.350
 Why?
Disease-Free Survival
6
2019
647
0.330
 Why?
Preoperative Care
3
2017
337
0.320
 Why?
Lymph Node Excision
3
2017
164
0.320
 Why?
Smooth Muscle Tumor
1
2009
6
0.320
 Why?
Leiomyosarcoma
1
2009
26
0.310
 Why?
United States
14
2024
13913
0.300
 Why?
Sarcoma, Alveolar Soft Part
1
2008
6
0.300
 Why?
Survival Rate
6
2021
1872
0.290
 Why?
Neoplasm Grading
7
2019
283
0.270
 Why?
Neoplasms, Second Primary
2
2019
106
0.270
 Why?
Radiotherapy, Adjuvant
3
2018
208
0.270
 Why?
Combined Modality Therapy
3
2020
1201
0.270
 Why?
Chemotherapy, Adjuvant
3
2018
377
0.260
 Why?
Insurance, Health
3
2018
269
0.260
 Why?
Cross-Sectional Studies
5
2017
5085
0.250
 Why?
Pregnancy Complications
2
2014
494
0.250
 Why?
Risk Factors
7
2024
9801
0.250
 Why?
Cohort Studies
5
2021
5444
0.240
 Why?
Young Adult
7
2021
12467
0.240
 Why?
Insurance Coverage
2
2018
220
0.240
 Why?
Paclitaxel
6
2024
218
0.240
 Why?
Lymphatic Metastasis
2
2019
320
0.230
 Why?
Databases, Factual
3
2021
1269
0.230
 Why?
Doxorubicin
2
2024
329
0.230
 Why?
Biomarkers, Tumor
4
2023
1161
0.220
 Why?
Self Report
2
2018
800
0.210
 Why?
Nomograms
2
2021
47
0.210
 Why?
Chemoradiotherapy
1
2024
208
0.210
 Why?
Lung Neoplasms
1
2016
2344
0.200
 Why?
Histone-Lysine N-Methyltransferase
1
2024
124
0.200
 Why?
Immunoglobulin M
1
2024
276
0.200
 Why?
Tertiary Care Centers
1
2023
153
0.200
 Why?
Factor Xa Inhibitors
1
2024
170
0.200
 Why?
Liver Diseases
1
2005
291
0.200
 Why?
Adolescent
6
2021
20451
0.190
 Why?
Program Evaluation
2
2018
878
0.190
 Why?
Organ Sparing Treatments
2
2019
32
0.190
 Why?
Quality of Life
4
2024
2695
0.190
 Why?
Platinum
1
2022
44
0.190
 Why?
Length of Stay
3
2015
1133
0.190
 Why?
Enzyme-Linked Immunosorbent Assay
1
2024
836
0.190
 Why?
beta Catenin
2
2023
224
0.180
 Why?
Immunohistochemistry
2
2023
1690
0.180
 Why?
BRCA2 Protein
1
2021
54
0.170
 Why?
BRCA1 Protein
1
2021
65
0.170
 Why?
Ovary
2
2019
209
0.170
 Why?
Risk Assessment
4
2024
3269
0.170
 Why?
Treatment Outcome
5
2020
10241
0.170
 Why?
High-Throughput Nucleotide Sequencing
1
2023
486
0.170
 Why?
Fallopian Tube Neoplasms
1
2019
15
0.160
 Why?
Immunoglobulin G
1
2024
851
0.160
 Why?
Cytoreduction Surgical Procedures
1
2020
59
0.160
 Why?
Withholding Treatment
1
2020
71
0.160
 Why?
Postoperative Hemorrhage
1
2020
88
0.160
 Why?
NM23 Nucleoside Diphosphate Kinases
1
2019
2
0.160
 Why?
Age Factors
4
2016
3161
0.160
 Why?
Polyethylene Glycols
1
2024
612
0.150
 Why?
Peritoneal Neoplasms
1
2019
86
0.150
 Why?
Incidence
3
2024
2646
0.150
 Why?
Pregnancy
4
2020
6423
0.150
 Why?
Cisplatin
4
2024
299
0.150
 Why?
CD8-Positive T-Lymphocytes
1
2024
855
0.150
 Why?
Cancer Survivors
1
2023
257
0.150
 Why?
Randomized Controlled Trials as Topic
2
2021
1368
0.140
 Why?
Fibrinolytic Agents
1
2020
262
0.140
 Why?
Stathmin
1
2017
2
0.140
 Why?
Carboplatin
3
2024
139
0.140
 Why?
Carcinoma, Adenosquamous
1
2017
10
0.140
 Why?
Neoadjuvant Therapy
1
2020
379
0.140
 Why?
Blood Loss, Surgical
2
2015
96
0.140
 Why?
Guideline Adherence
1
2021
527
0.130
 Why?
Carcinoma
1
2019
213
0.130
 Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2017
25
0.130
 Why?
Societies, Medical
1
2021
759
0.130
 Why?
Socioeconomic Factors
1
2021
1214
0.130
 Why?
Health Status Disparities
2
2017
256
0.130
 Why?
Case-Control Studies
4
2019
3384
0.130
 Why?
National Cancer Institute (U.S.)
1
2016
43
0.130
 Why?
Perioperative Care
1
2018
166
0.130
 Why?
Neonatology
1
2016
23
0.130
 Why?
Benzamides
1
2017
203
0.130
 Why?
Uterus
2
2023
207
0.130
 Why?
Surgical Oncology
1
2016
22
0.130
 Why?
Carcinoma, Squamous Cell
2
2021
628
0.130
 Why?
Marriage
1
2017
116
0.120
 Why?
Reimbursement Mechanisms
1
2016
84
0.120
 Why?
Piperidines
1
2017
200
0.120
 Why?
Bevacizumab
3
2021
128
0.120
 Why?
Drug Costs
1
2016
100
0.120
 Why?
Pneumonia, Viral
1
2020
342
0.120
 Why?
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
1
2015
17
0.120
 Why?
Coronavirus Infections
1
2020
336
0.120
 Why?
Mutation
2
2023
3706
0.120
 Why?
Female Urogenital Diseases
1
2014
5
0.120
 Why?
Pregnancy Complications, Neoplastic
1
2015
52
0.120
 Why?
Intraoperative Complications
1
2015
129
0.110
 Why?
Morbidity
1
2015
302
0.110
 Why?
Peritoneal Cavity
1
2014
31
0.110
 Why?
Surgical Wound Dehiscence
1
2014
23
0.110
 Why?
Blood Volume
1
2014
61
0.110
 Why?
Hemostatics
1
2014
50
0.110
 Why?
Maternal-Fetal Exchange
1
2015
162
0.110
 Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2017
340
0.110
 Why?
Drainage
1
2014
164
0.110
 Why?
Colposcopy
1
2013
15
0.100
 Why?
Health Policy
1
2016
354
0.100
 Why?
Needs Assessment
1
2015
357
0.100
 Why?
Antibodies
1
2015
399
0.100
 Why?
Referral and Consultation
1
2018
735
0.100
 Why?
Patient Readmission
1
2018
668
0.100
 Why?
Prospective Studies
6
2023
7158
0.100
 Why?
Early Detection of Cancer
1
2016
371
0.090
 Why?
Pandemics
1
2020
1500
0.090
 Why?
Poly-ADP-Ribose Binding Proteins
2
2023
33
0.090
 Why?
DNA Polymerase II
2
2023
38
0.090
 Why?
Clinical Trials as Topic
1
2016
1005
0.090
 Why?
Proportional Hazards Models
3
2021
1199
0.090
 Why?
Surgical Wound Infection
1
2014
283
0.090
 Why?
Fetus
1
2015
782
0.090
 Why?
Kaplan-Meier Estimate
1
2013
851
0.090
 Why?
Benzimidazoles
2
2021
162
0.080
 Why?
Multivariate Analysis
1
2013
1501
0.080
 Why?
Multicenter Studies as Topic
2
2021
287
0.080
 Why?
Metrorrhagia
1
2008
4
0.080
 Why?
Dilatation and Curettage
1
2008
11
0.070
 Why?
Pediatrics
1
2016
1074
0.070
 Why?
Surveys and Questionnaires
2
2018
5437
0.070
 Why?
Male
7
2024
63759
0.070
 Why?
Tumor Suppressor Protein p53
2
2023
503
0.070
 Why?
Quality Improvement
1
2015
1112
0.070
 Why?
SEER Program
2
2018
202
0.070
 Why?
Models, Biological
1
2014
1724
0.070
 Why?
Rupture, Spontaneous
1
2005
18
0.060
 Why?
Budd-Chiari Syndrome
1
2005
5
0.060
 Why?
Hepatolenticular Degeneration
1
2005
15
0.060
 Why?
HELLP Syndrome
1
2005
6
0.060
 Why?
Hematoma
1
2005
53
0.060
 Why?
Hepatitis B
1
2005
66
0.060
 Why?
Obesity
2
2016
2885
0.060
 Why?
Tomography, X-Ray Computed
1
2014
2511
0.060
 Why?
Cost-Benefit Analysis
2
2020
569
0.060
 Why?
Colorado
1
2014
4410
0.060
 Why?
Anti-Bacterial Agents
1
2014
1708
0.060
 Why?
Histocompatibility Antigens
1
2024
107
0.050
 Why?
DNA Mismatch Repair
1
2023
47
0.050
 Why?
Decision Support Techniques
2
2020
401
0.050
 Why?
Pre-Eclampsia
1
2005
187
0.050
 Why?
Fatty Liver
1
2005
230
0.050
 Why?
Liposomes
1
2024
171
0.050
 Why?
Hepatitis C
1
2005
244
0.050
 Why?
Cholestasis
1
2005
232
0.050
 Why?
Acute Disease
1
2005
980
0.050
 Why?
X-ray Repair Cross Complementing Protein 1
1
2022
12
0.050
 Why?
Medical Futility
1
2022
23
0.050
 Why?
Claudin-4
1
2022
15
0.050
 Why?
Genes, BRCA2
1
2021
22
0.040
 Why?
Genes, BRCA1
1
2021
30
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2021
51
0.040
 Why?
Hematologic Diseases
1
2021
61
0.040
 Why?
Critical Care
1
2005
552
0.040
 Why?
DNA Repair
1
2022
210
0.040
 Why?
Life Style
1
2023
462
0.040
 Why?
Organoplatinum Compounds
1
2020
41
0.040
 Why?
Topotecan
1
2020
12
0.040
 Why?
Quality-Adjusted Life Years
1
2020
106
0.040
 Why?
Drug Resistance, Neoplasm
1
2024
753
0.040
 Why?
Injections, Intraperitoneal
1
2019
112
0.040
 Why?
DNA Damage
1
2022
383
0.040
 Why?
Japan
1
2019
98
0.040
 Why?
Injections, Intravenous
1
2019
202
0.040
 Why?
Platinum Compounds
1
2019
10
0.040
 Why?
Infusions, Intravenous
1
2020
402
0.040
 Why?
Microsatellite Instability
1
2019
38
0.040
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
81
0.040
 Why?
Angiogenesis Inhibitors
1
2020
218
0.040
 Why?
PTEN Phosphohydrolase
1
2019
159
0.040
 Why?
Administration, Oral
1
2020
787
0.040
 Why?
Survival Analysis
1
2021
1271
0.030
 Why?
Antineoplastic Agents, Phytogenic
1
2019
187
0.030
 Why?
Betacoronavirus
1
2020
252
0.030
 Why?
Cell Line, Tumor
1
2024
3185
0.030
 Why?
Hospitals, Private
1
2016
12
0.030
 Why?
Health Facility Size
1
2016
11
0.030
 Why?
Time Factors
2
2017
6550
0.030
 Why?
Patient Reported Outcome Measures
1
2020
374
0.030
 Why?
Hospitals, Teaching
1
2016
114
0.030
 Why?
Odds Ratio
1
2018
1022
0.030
 Why?
ErbB Receptors
1
2019
605
0.030
 Why?
Social Class
1
2017
259
0.030
 Why?
Medically Uninsured
1
2016
128
0.030
 Why?
Ileus
1
2015
12
0.030
 Why?
Salpingectomy
1
2015
13
0.030
 Why?
Dose-Response Relationship, Drug
1
2019
2016
0.030
 Why?
Income
1
2016
188
0.030
 Why?
Diet
1
2023
1212
0.030
 Why?
Urinary Retention
1
2015
20
0.030
 Why?
Elective Surgical Procedures
1
2016
165
0.030
 Why?
Advisory Committees
1
2016
216
0.030
 Why?
Pelvis
1
2015
104
0.030
 Why?
Critical Pathways
1
2014
86
0.030
 Why?
Urban Population
1
2016
443
0.030
 Why?
Papanicolaou Test
1
2013
42
0.030
 Why?
Vaginal Smears
1
2013
55
0.030
 Why?
Clinical Protocols
1
2014
254
0.030
 Why?
Membrane Proteins
1
2019
1119
0.020
 Why?
Pregnancy Outcome
1
2015
392
0.020
 Why?
Rural Population
1
2016
521
0.020
 Why?
Exercise
1
2023
1934
0.020
 Why?
Disease Progression
1
2019
2628
0.020
 Why?
Polymorphism, Single Nucleotide
1
2019
2062
0.020
 Why?
Comorbidity
1
2016
1551
0.020
 Why?
Biomedical Research
1
2016
640
0.020
 Why?
Curriculum
1
2016
928
0.020
 Why?
Colorectal Neoplasms
1
2016
748
0.020
 Why?
Prostatic Neoplasms
1
2016
999
0.020
 Why?
Patient Discharge
1
2015
856
0.020
 Why?
Mice
1
2024
16983
0.020
 Why?
Breast Neoplasms
1
2016
2104
0.010
 Why?
Infant, Newborn
1
2015
5772
0.010
 Why?
Animals
1
2024
35409
0.010
 Why?
Guntupalli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (286) concept(s)
_
Co-Authors Expand Description
See all (35) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)